- Alnylam Pharmaceuticals: Stifel raised the target to $247 from $215. Maintains buy rating.
- Avis Budget Group: Deutsche Bank maintains hold rating. PT up to $229 from $184.
- Boston Properties: SMBC Nikko cut the recommendation to neutral from outperform. PT up 5.2% to $93.
- Centrica: HSBC raised the recommendation to hold from reduce. PT set to 90 pence.
- CF Industries Holdings: Scotiabank raised the recommendation to sector outperform from sector perform. PT up 21% to $118.
- Charles River Laboratories International: Morgan Stanley moves to equal-weight from overweight. PT up 13% to $250.
- DuPont de Nemours: Deutsche Bank maintains buy rating. PT up 20% to $70.
- Eaton: UBS downgrades price target to $173 from $192.
- Encompass Health: BMO Capital Markets maintains outperform rating. PT down to $65 from $83.
- Exact Sciences: Raymond James maintains outperform rating. PT down to $70 from $80.
- Healthpeak Properties: Stifel cut the target to $34 from $40. Maintains buy rating.
- Henry Schein: Credit Suisse maintains outperform rating. PT up 19% to $90.
- Illinois Tool Works: Stifel maintains hold rating. PT up to $192 from $163.
- Marathon Petroleum: RBC Capital Markets raised the target to $121 from $110. Maintains outperform rating.
- Microchip Technology: Needham & Co raised the target. Maintains buy rating. PT up 33%.
- Zebra Technologies: Needham & Co downgrades price target to $450 from $500.
- Zimmer Biomet Holdings: Stifel maintains buy rating. PT up to $135 from $120.